346 related articles for article (PubMed ID: 15510599)
1. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
[TBL] [Abstract][Full Text] [Related]
2. Studies in longstanding ulcerative colitis with special reference to malignant transformation of the colorectal mucosa.
Löfberg R
Acta Chir Scand Suppl; 1989; 552():1-45. PubMed ID: 2800882
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer in colonic Crohn's disease--high frequency of DNA-aneuploidy.
Sjöqvist U; Befrits R; Söderlund S; Ost A; Karlén P; Tribukait B; Rubio C; Rutgeerts P; Geboes K; Löfberg R
Anticancer Res; 2005; 25(6C):4393-7. PubMed ID: 16334114
[TBL] [Abstract][Full Text] [Related]
4. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
5. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
[TBL] [Abstract][Full Text] [Related]
7. Early onset of ulcerative colitis: long-term follow-up with special reference to colorectal cancer and primary sclerosing cholangitis.
Lindberg J; Stenling R; Palmqvist R; Rutegård J
J Pediatr Gastroenterol Nutr; 2008 May; 46(5):534-8. PubMed ID: 18493208
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
Alberts DS; Martínez ME; Hess LM; Einspahr JG; Green SB; Bhattacharyya AK; Guillen J; Krutzsch M; Batta AK; Salen G; Fales L; Koonce K; Parish D; Clouser M; Roe D; Lance P;
J Natl Cancer Inst; 2005 Jun; 97(11):846-53. PubMed ID: 15928305
[TBL] [Abstract][Full Text] [Related]
9. Chronic inflammatory bowel disease and cancer.
Pohl C; Hombach A; Kruis W
Hepatogastroenterology; 2000; 47(31):57-70. PubMed ID: 10690586
[TBL] [Abstract][Full Text] [Related]
10. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic screening for dysplasia and mucosal aneuploidy in adolescents and young adults with childhood onset colitis.
Markowitz J; McKinley M; Kahn E; Stiel L; Rosa J; Grancher K; Daum F
Am J Gastroenterol; 1997 Nov; 92(11):2001-6. PubMed ID: 9362180
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].
Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL
Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026
[TBL] [Abstract][Full Text] [Related]
13. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
Rubin DT; LoSavio A; Yadron N; Huo D; Hanauer SB
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1346-50. PubMed ID: 17059900
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
15. Carcinogenesis in inflammatory bowel disease.
Herszenyi L; Miheller P; Tulassay Z
Dig Dis; 2007; 25(3):267-9. PubMed ID: 17827953
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel disease as a risk factor for colorectal cancer.
Lukas M
Dig Dis; 2010; 28(4-5):619-24. PubMed ID: 21088413
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.
Vera A; Gunson BK; Ussatoff V; Nightingale P; Candinas D; Radley S; Mayer A; Buckels JA; McMaster P; Neuberger J; Mirza DF
Transplantation; 2003 Jun; 75(12):1983-8. PubMed ID: 12829898
[TBL] [Abstract][Full Text] [Related]
18. Dysplasia in inflammatory bowel disease.
Greenson JK
Semin Diagn Pathol; 2002 Feb; 19(1):31-7. PubMed ID: 11936264
[TBL] [Abstract][Full Text] [Related]
19. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group.
van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR
Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric DNA analysis of ulcerative colitis using paraffin-embedded biopsy specimens: comparison with morphology and DNA analysis of fresh samples.
Hartmann DP; Montgomery EA; Carr NJ; Gupta PK; Azumi N
Am J Gastroenterol; 1995 Apr; 90(4):590-6. PubMed ID: 7717317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
